Skincare Manufacturing: FDA GMP Rule Slips to November 2027
The federal good manufacturing practice rule for skincare manufacturing is now scheduled for November 2027 — almost three years after the deadline Congress set for it. The latest Unified Agenda lists FDA’s cosmetic GMP rulemaking (RIN 0910-AJ00) as a “Long-Term Action” with a proposed-rule date of 11/00/2027, where the previous agenda said only “To Be Determined”. For brand owners, the practical effect is the opposite of relief: there is still no federal GMP baseline to point at, so the burden of proving a factory is competent stays entirely with you.
What the agenda actually changed
The Modernization of Cosmetics Regulation Act of 2022 told FDA to establish GMP requirements by regulation for facilities that manufacture or process cosmetic products. The statutory timetable, as summarized by the Congressional Research Service, required a proposed rule by December 29, 2024 and a final rule by December 29, 2025. Neither happened.
The agenda entry is worth reading carefully, because it tells you more than the date. The rule is marked “Economically Significant”, it is destined for a new 21 CFR part 711, and it flags small entities as affected. A November 2027 proposed rule means a comment period after that, then a final rule, then a compliance date. Anyone budgeting for federal cosmetic GMP obligations should be thinking about the end of the decade, not next year.
Why “no rule yet” is not the same as “no standard”
This is where founders get caught. The absence of a finished GMP regulation does not create a gap in the law, and it does not make a sloppy factory legal. The adulteration provisions of the Federal Food, Drug, and Cosmetic Act apply now. A cosmetic prepared or held under insanitary conditions where it may have become contaminated is adulterated regardless of whether part 711 exists yet, and FDA keeps its inspection authority over registered facilities in the meantime.
FDA’s own cosmetic GMP document is still marked draft and “not for implementation”, containing non-binding recommendations. It was drafted with reference to ISO 22716:2007, the international cosmetics GMP standard, as part of a harmonization effort through the International Cooperation on Cosmetic Regulations. That is the most useful signal in the whole file: the standard the eventual rule is expected to draw on already exists, is already auditable, and is already certifiable today.
What is enforceable right now, in 2026
Plenty. While GMP waits, the rest of MoCRA is live, and most of it lands on the brand rather than the factory. If your name is on the label you are the “responsible person”, and that carries obligations the manufacturer cannot absorb for you:
- Facility registration and biennial renewal sit with the manufacturer — and the renewal date is keyed to that facility’s initial registration date, not a common annual cycle. Ask for it in writing.
- Product listing — each marketed product, with its ingredients, listed with FDA and updated annually — is the responsible person’s job.
- Safety substantiation records must exist and be maintained. FDA does not prescribe specific tests, which means nobody is going to hand you a template; the records still have to be adequate.
- Serious adverse event reports go to FDA within 15 business days, with a copy of the retail label, and new information within a year of the first report must follow within 15 business days.
- Do not expect a compliance certificate. In September 2026 FDA stated plainly that it does not issue certificates or other documents verifying compliance for cosmetic facility registration. A supplier offering one is offering something that does not exist.
It is also worth being precise about approval, because the misuse of that word is endemic in supplier marketing. FDA does not pre-approve cosmetic products or the facilities that make them, with the narrow exception of certain color additives. Registration is a filing obligation. It is meaningful — it puts a facility on the record and within inspection reach — but it is not a seal.
How to judge a skincare manufacturing partner while the rule is pending
With no federal GMP rule to cite, due diligence falls back on things you can actually verify. Three questions do most of the work. First: are you certified to ISO 22716, and can I download the certificate and check it with the issuing body? Second: what is your facility registration renewal date? Third: which MoCRA records will you give me, and which are mine to build — batch records, ingredient documentation, stability data, safety substantiation inputs?
A factory that answers those three crisply has already told you how it will behave when part 711 arrives. A factory that answers with adjectives has told you something too.
Where Moe’s Group stands
Moe’s Group manufactures skincare, hair care and body care at a Chatsworth, California facility that is registered with FDA and certified to ISO 22716:2007 for cosmetics GMP, alongside ISO 9001:2015 and ISO 45001:2018. Every certificate is downloadable in full and verifiable with the issuing body rather than taken on trust. Existing-formula white label work starts at 200 units; custom formulation starts at 1,000 units; facility capacity is up to one million units a month, which describes the plant rather than any individual project’s lead time.
If you are scoping a launch and want to know which records will be yours and which will be ours before you commit, send us the brief.
— The Moe’s Group Newsroom
